Brexit bad for orphans: Concerns about cost to rare disease-focused UK pharma

By Gareth Macdonald contact

- Last updated on GMT


Related tags: European union

Eurodis says Brexit-related costs and admin burden placed on UK pharma may affect availability of drugs for rare diseases and discourage development of such products.

All drug firms with UK-registered marketing authorisations will need to transfer them, along with batch release and pharmacovigilance activities, to an operation established in the EU or EEA after the UK withdraws from the European Union on March 29, 2019​. 

The rule - set out in According to Article 2 of Regulation (EC) No 726/2004​ - applies to UK-registered manufacturers of orphan drugs (OD) according to a representative of the European Medicines Agency (EMA).

He told us “Marketing authorisation holders [for drugs for rare disease] will be required to adapt processes and to consider changes to the terms of the marketing authorisation in order to ensure its continuous validity, once the UK has left the EU​.”

Developers have been able to seek orphan designation in the European Union (EU) since the year 2000 under regulations designed to encourage the development of medicines for smaller patient populations.

To date, the EMA has classified 1,900 candidate products as orphan drugs, 140 of which are commercially available.

According to the agency representative, “There are 52 products, authorised in the EU for the treatment of a rare disease, whose marketing authorisation holders are registered in the UK​.”


Virginie Hivert from Eurodis, a non-governmental organisation representing patient groups and individuals active in the field of rare diseases, raised concerns that Brexit will change drug availability and impact future research spending.

We are concerned that the consequences of Brexit may have an impact on patients’ access to rare disease treatments. 

“Recent news that funding that would have been otherwise earmarked for therapeutic development will need to be diverted to the relocation of headquarters and manufacturing facilities is discouraging​” she said.

Hivert added that while the outcome for patients is difficult to assess before Brexit negotiations are completed, any relocation or administrative costs incurred by drug developers are likely to impact prices.

If the UK leaves the single market there will likely be an inflation in the costs of pharmaceutical products as, unless a special agreement is reached, industry will have to adopt costly measures to run regulatory affairs in the UK and also in the EU.

Related news

Show more

Related products

show more

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Related suppliers

Follow us


View more